96.06
Schlusskurs vom Vortag:
$98.47
Offen:
$99.4
24-Stunden-Volumen:
1.15M
Relative Volume:
1.53
Marktkapitalisierung:
$6.41B
Einnahmen:
$136.86M
Nettoeinkommen (Verlust:
$-168.69M
KGV:
-34.19
EPS:
-2.81
Netto-Cashflow:
$-113.49M
1W Leistung:
-7.52%
1M Leistung:
-8.42%
6M Leistung:
-0.41%
1J Leistung:
+66.66%
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
RYTM
Rhythm Pharmaceuticals Inc
|
96.06 | 6.57B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Eingeleitet | Citigroup | Buy |
| 2025-11-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-07-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2025-01-02 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Guggenheim | Buy |
| 2024-09-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Rhythm’s LB54640 Trial Completion Sets Up Key Catalyst in Hypothalamic Obesity - TipRanks
Jobs Data: Is Atossa Therapeutics Incs growth already priced inJuly 2025 Price Swings & Stepwise Swing Trade Plans - baoquankhu1.vn
Earnings Miss: Can Rhythm Pharmaceuticals Inc expand into new marketsStock Surge & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Rhythm Pharmaceuticals at Guggenheim Summit: Expanding Horizons in Biotech By Investing.com - Investing.com Canada
Earnings Risk: Is Rhythm Pharmaceuticals Inc currently under institutional pressure2025 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Rhythm Pharma label expansion requests for obesity drug undergo U.S. EU reviews - MSN
Candriam S.C.A. Lowers Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals prices $175M stock offering - MSN
Bond Watch: Will Rhythm Pharmaceuticals Inc benefit from green energy policies2025 Growth vs Value & Short-Term Trading Alerts - baoquankhu1.vn
Smith, Rhythm Pharmaceuticals CFO, sells $702k in RYTM stock By Investing.com - Investing.com Canada
Insider Sell: Hunter Smith Sells Shares of Rhythm Pharmaceuticals Inc (RYTM) - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Sells $358,588.86 in Stock - MarketBeat
Penserra Capital Management LLC Acquires Shares of 30,436 Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals' CFO Hunter C. Smith to Speak at Guggenheim Emerging Outlook: Biotech Summit 2026 - Quiver Quantitative
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit - ChartMill
Rhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by New York State Common Retirement Fund - MarketBeat
How Rhythm Pharmaceuticals Inc. (RYTM) Affects Rotational Strategy Timing - Stock Traders Daily
WCM Investment Management LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
This High-Flying Growth Stock Is Hiding in Plain Sight - Finviz
Federated Hermes Inc. Has $174.50 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
EFG Asset Management North America Corp. Invests $2.05 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Bank Watch: Will Rhythm Pharmaceuticals Inc stock go up in YEARMarket Weekly Review & Daily Price Action Insights - baoquankhu1.vn
Aug Breakouts: What hedge funds are buying Rhythm Pharmaceuticals IncWall Street Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 37.5% Potential Upside in Biotech - DirectorsTalk Interviews
Aug Technicals: Is INVO Fertility Inc stock heavily shortedJuly 2025 Earnings & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
(RYTM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
What is HC Wainwright's Estimate for RYTM FY2025 Earnings? - MarketBeat
When Will Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Turn A Profit? - Yahoo Finance
Zacks Research Downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to Strong Sell - MarketBeat
Earnings Miss: Will Rhythm Pharmaceuticals Inc stock go up in YEARTake Profit & Weekly Return Optimization Alerts - baoquankhu1.vn
Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals - MSN
Rhythm Pharmaceuticals stock price target raised to $125 from $123 at H.C. Wainwright - Investing.com Canada
Breaking Down Rhythm Pharmaceuticals: 13 Analysts Share Their Views - Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for RYTM with Increased Price Target | RYTM Stock News - GuruFocus
Obesity Market on Track for Major Expansion by 2034, According to DelveInsight | Rhythm Pharmaceuticals, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharm - Barchart.com
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Strong IMCIVREE Revenue Guidance For 2025 - Sahm
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 5.3%Time to Sell? - MarketBeat
SG Americas Securities LLC Buys 13,369 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals, Inc. $RYTM Holdings Lifted by Nisa Investment Advisors LLC - MarketBeat
Responsive Playbooks and the RYTM Inflection - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Gem with 38% Potential Upside - DirectorsTalk Interviews
What Rhythm Pharmaceuticals (RYTM)'s Strong IMCIVREE Revenue Beat Means For Shareholders - Sahm
Rhythm Pharmaceuticals stock price target raised to $130 from $120 at TD Cowen - Investing.com Canada
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March - Stocktwits
Needham Raises Price Target for Rhythm Pharmaceuticals (RYTM) to $148 | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Rhythm Pharmaceuticals (RYTM) Projects Strong Revenue Growth for 2025 - GuruFocus
Rhythm Pharmaceuticals announces preliminary, unaudited fourth quarter results - marketscreener.com
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones - The Manila Times
How cyclical is Rhythm Pharmaceuticals Inc. (1RV) stock compared to rivalsJuly 2025 Reactions & High Win Rate Trade Tips - Улправда
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):